Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland +1 locations
Conditions: Non-small Cell Lung Cancer
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Completed
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells. Giving chemotherapy or radiation therapy before or after transplant also stops the patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem cells may replace the patient's immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the... Read More
Gender:
ALL
Ages:
Between 6 months and 74 years
Trial Updated:
09/02/2015
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
Completed
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance the effectiveness of graft-versus-host disease to kill cancer cells. PURPOSE: Randomized phase III trial to determine the effectiveness of graft-versus-host disease in treating patients who have recurrent or refractory lymphoma or Hodgkin's disease .
Gender:
ALL
Ages:
All
Trial Updated:
07/16/2015
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Graft Versus Host Disease, Lymphoma
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III tri... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2015
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Completed
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
01/29/2015
Locations: The Sydney Kimmel Comprehensive Cancer center, Baltimore, Maryland
Conditions: Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have recurrent or refractory Hodgkin's lymphoma or non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/31/2014
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +2 locations
Conditions: Lymphoma
Combination Chemotherapy in Treating Children With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland +3 locations
Conditions: Neuroblastoma
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of etoposide plus radiation therapy followed by combination chemotherapy in treating children with newly diagnosed advanced medulloblastoma.
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
07/24/2014
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without dexrazoxane in treating children who have Hodgkin's disease.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/23/2014
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Cardiac Toxicity, Lymphoma
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow transplantation and/or peripheral stem cell transplantation in treating patients who have recurrent medulloblas... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
07/23/2014
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Brain Tumor, Central Nervous System Tumor
Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/23/2014
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +2 locations
Conditions: Kidney Cancer
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Completed
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2014
Locations: University of Maryland Medical Center - Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Lymphoma